Kerry Rogers, MD, discusses an important unmet need in patients with hairy cell leukemia.
Kerry Rogers, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discusses an important unmet need in patients with hairy cell leukemia. She says it is important to realize, though, that many of these patients receive a single dose of pentostatin or cladribine or a single course and are alive without leukemia recurrence 8 to 10 years later.
For these patients who receive either pentostatin or cladribine, complications can still happen, although hairy cell leukemia, in most cases, will not shorten a patient’s natural life span. One side effect patients experience more frequently is infection, which can be severe or life-threatening. Patients can also develop infection after treatment, especially if they receive treatment with purine nucleoside analogs.
Rogers says that it is important now to find better therapies for patients with hairy cell leukemia that provider better supportive care and management surrounding infection.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More